Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Cost of Revenue: 2009-2025

Historic Cost of Revenue for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $815,871.

  • China Pharma Holdings' Cost of Revenue fell 49.63% to $815,871 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 39.65%. This contributed to the annual value of $6.5 million for FY2024, which is 10.67% down from last year.
  • Latest data reveals that China Pharma Holdings reported Cost of Revenue of $815,871 as of Q3 2025, which was down 26.68% from $1.1 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Cost of Revenue high stood at $2.9 million for Q4 2022, and its period low was $815,871 during Q3 2025.
  • In the last 3 years, China Pharma Holdings' Cost of Revenue had a median value of $1.6 million in 2024 and averaged $1.5 million.
  • Per our database at Business Quant, China Pharma Holdings' Cost of Revenue skyrocketed by 55.91% in 2024 and then crashed by 49.63% in 2025.
  • Quarterly analysis of 5 years shows China Pharma Holdings' Cost of Revenue stood at $2.6 million in 2021, then grew by 11.24% to $2.9 million in 2022, then fell by 22.56% to $2.2 million in 2023, then crashed by 41.92% to $1.3 million in 2024, then tumbled by 49.63% to $815,871 in 2025.
  • Its Cost of Revenue stands at $815,871 for Q3 2025, versus $1.1 million for Q2 2025 and $1.3 million for Q1 2025.